Dare Bioscience

Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert and Roger L. Hawley in 2015 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Daré Bioscience reports Q1 progress in women's health innovation

Daré Bioscience showcased progress in Q1 2024 with achievements in product commercialization and pipeline advancements, despite a reported comprehensive loss.
The company's focus on women's health innovation and commitment to driving value for stakeholders position them well for future growth.
While facing financial challenges and competitive pressures, Daré Bioscience has opportunities to capitalize on its strong pipeline and attract investor interest.
Continued momentum in Phase III studies and technology development present avenues for growth and market expansion in the women's health sector.

Dare Bioscience reports strong Q2 earnings, advances women's health therapies

Dare Bioscience delivered a robust Q2 2024 performance marked by cost efficiencies, revenue generation from strategic transactions, and progress in key product developments.
The company's focus on women's health and commitment to advancing therapies position it well for future growth and market leadership in a segment with significant unmet needs.
While facing challenges in market adoption and regulatory interactions, Dare Bioscience has opportunities to drive revenue growth, expand its market presence, and diversify its product portfolio.
Overall, Dare Bioscience's Q2 earnings call reflects a company on a positive trajectory, with a strong financial foundation and a strategic focus on advancing innovative solutions for women's health.

Daré Bioscience reports cost reductions and promising pipeline developments

Daré Bioscience showcased strong financial discipline with notable expense reductions and strategic funding acquisitions, positioning the company for sustainable growth.
Progress in late-stage candidates and FDA interactions signals promising developments in the pipeline, underscoring Daré's commitment to innovation in women's health.
While facing financial challenges and operational hurdles, Daré's focus on disruptive products and leveraging funding opportunities presents avenues for future success.
Overall, Daré Bioscience's Q3 performance reflects a balance of cost management, innovation, and strategic positioning in the healthcare market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO, March 23, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Tuesday, March 30, 2021, to review its financial results for the year ended December 31, 2020 and to provide a Company update.

Daré Bioscience to Host Full Year 2020 Financial Results and Company Update Conference Call and Webcast on March 30, 2021

SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will participate in the following upcoming virtual conferences:

Daré Bioscience to Participate in Upcoming Virtual Conferences

SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will participate in a panel discussion for Maxim Group LLC's Late Stage Innovations in Women's Health event, which is part of the M-Vest Virtual Conference Series. The virtual event will take place at 11:00 am Eastern Time on March 4, 2021.

Daré Bioscience to Participate in Maxim Group's Late Stage Innovations in Women's Health Virtual Event

SAN DIEGO, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will participate in a live panel discussion titled, The Evolution of Birth Control: Considerations from Product Development to End-User Adoption from Leading Innovators, at 12:30 p.m. EST / 9:30 a.m. PST on Tuesday, February 23, 2021, at the Women's Health Innovation Series: Contraception Innovation Summit, which will be held virtually.

Daré Bioscience to Participate at the Women's Health Innovation Series: Contraception Innovation Summit to be held Virtually on February 23, 2021

Shares of Daré Bioscience look poised to double between yesterday and today. DARE stock is an investment in women's health niches.

DARE Stock: Why Daré Bioscience Is on the Move Today

The stock price of Daré Bioscience Inc (NASDAQ: DARE) is up more than 55% pre-market today. This is why it happened.

DARE Stock Price Increases Over 55% Pre-Market: Why It Happened

Medicenna Therapeutics Corp

Sonoma Pharmaceuticals

Sonoma Pharmaceuticals (NASDAQ: SNOA) shares are trading higher on Friday after the company announced a partnership with Gabriel Science for dental markets. Sonoma is engaged in identifying, developing and commercializing differentiated therapies to patients living with chronic skin conditions.

Why Sonoma, Medicenna And Dare Bioscience Are Trading Higher Today

Daré Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q3 2020 Results - Earnings Call Transcript

Shares of Dare Bioscience (NASDAQ:DARE) moved higher by 0.9% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share decreased 20.00% year over year to ($0.24), which missed the estimate of ($0.17).

Recap: Dare Bioscience Q3 Earnings

Conference Call Today at 4:30 p.m. Eastern Time Conference Call Today at 4:30 p.m. Eastern Time

Daré Bioscience Reports Third Quarter 2020 Financial Results and Provides Company Update

SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, November 12, 2020, to review its financial results for the quarter ended September 30, 2020 and to provide a Company update.

Daré Bioscience to Host Third Quarter 2020 Financial Results and Company Update Conference Call and Webcast on November 12, 2020

SAN DIEGO, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, President and Chief Executive Officer, will present at the 2020 BIO Investor Forum, which will be held in a digital format October 13-15, 2020. The company presentation will be available on demand during the virtual event for all registered attendees.

Daré Bioscience to Present at the 2020 BIO Investor Forum Digital

Contraceptive Program Supported by approximately $20.5 Million in Grant Funding from the Bill & Melinda Gates Foundation to Date Contraceptive Program Supported by approximately $20.5 Million in Grant Funding from the Bill & Melinda Gates Foundation to Date

Daré Bioscience Receives $0.9 million Under the Current Grant Supplement Award for Continued Development of its User-Controlled, Long Acting Reversible Contraceptive (DARE-LARC1)

Dare Bioscience: Preparing For The Upcoming Phase 3 Results

SAN DIEGO, Sept.  08, 2020  (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, Daré’s President and CEO, will participate in two upcoming virtual conferences:

Daré Bioscience Announces Participation in Two Upcoming Virtual Conferences

Agreement Intended to Facilitate Advancement of Daré’s Programs in a Capital Efficient Manner; Includes Economic Structures and Opportunities for Dedicated Staff Agreement Intended to Facilitate Advancement of Daré’s Programs in a Capital Efficient Manner; Includes Economic Structures and Opportunities for Dedicated Staff

Daré Bioscience and Avomeen Form Strategic Partnership to Accelerate the Development of Daré’s Novel Pipeline of Women’s Health Programs

SAN DIEGO, Aug.  19, 2020  (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it received a Notice of Award of a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a division of the National Institutes of Health (NIH). The award will support the clinical development of its novel intravaginal ring (IVR), DARE-FRT1. DARE-FRT1 is designed to deliver bio-identical progesterone continuously over a 14-day period and is being developed as a more convenient treatment option for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization regimen.

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-FRT1 Phase 1 Human Clinical Study for the Prevention of Pre

Daré Bioscience, Inc.'s (DARE) CEO Sabrina Martucci Johnson on Q2 2020 Results - Earnings Call Transcript

SAN DIEGO, Aug.  06, 2020  (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, President and Chief Executive Officer, will participate in a panel discussion during Maxim Group’s M-Vest Virtual Conference Series: Leading Innovators in Women’s Health, beginning at 10:00 a.m. Eastern Time on Thursday, August 13, 2020.

Daré Bioscience CEO to Participate in Maxim Group’s Leading Innovators in Women’s Health Virtual Conference

SAN DIEGO, Aug.  05, 2020  (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Wednesday, August 12, 2020, to review its financial results for the quarter ended June 30, 2020 and to provide a Company update.

Daré Bioscience to Host Second Quarter 2020 Financial Results and Company Update Conference Call and Webcast on August 12, 2020

More than 45 million women in the U.S. are approaching or in menopause More than 45 million women in the U.S. are approaching or in menopause

Daré Bioscience Announces Initiation of Phase 1 Clinical Trial of DARE-HRT1, a Novel Intravaginal Ring Designed to Deliver Non-oral, Bio-identical Hormone Therapy for the Treatment of Menopausal Symptoms

Includes positive clinical findings from a postcoital test (PCT) human clinical study of Ovaprene®, an investigational hormone-free, monthly contraceptive

Daré Bioscience Announces Publication of a Peer-Reviewed Journal Article Supporting the Use of the Postcoital Test Study as a Predictor of Contraceptive Effectiveness by Biology of Reproduction

Topline data readout anticipated by the end of 2020 Topline data readout anticipated by the end of 2020

Daré Bioscience Announces Initiation of Pivotal Phase 3 Study of DARE-BV1 in Patients with Bacterial Vaginosis

Contraceptive Program Supported by up to $20.5 Million in Grant Funding from the Bill & Melinda Gates Foundation Contraceptive Program Supported by up to $20.5 Million in Grant Funding from the Bill & Melinda Gates Foundation

Daré Bioscience Announces Receipt of $1.5 Million Under the Current Grant Supplement Award for Continued Development of User-Controlled Long Acting Reversible Contraceptive

Daré Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q1 2020 Results - Earnings Call Transcript

News for Dare Bioscience Stock (DARE)